Study guide

15.1 Pain Assessment and Management

Certified Pediatric Hematology Oncology Nurse CPHON®

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy

2 Care Continuum

2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship

3 Leukemias and Lymphomas

3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas

4 CNS, Neuroblastoma, and Renal Tumors

4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors

5 Sarcomas and Other Solid Tumors

5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

6 Hematologic Disorders

6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure

7 Pathophysiology, Genetics, and Diagnostics

7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis

8 Clinical Trials and Professional Performance

8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education

9 Chemotherapy and Biotherapy

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy

10 Immunotherapy, Cellular Therapy, and Radiation

10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

11 HSCT, Surgery, Transfusion, and Coagulation Therapy

11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy

12 Neurologic, Respiratory, and Cardiovascular Effects

12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects

13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects

13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects

14 Endocrine, Hematologic, Immunologic, and Sensory Effects

14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects

15 Pain, Sleep, Fatigue, and Mental Health

15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects

16 Supportive Care

16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care

17 Infectious and Gastrointestinal Emergencies

17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction

18 Metabolic Emergencies

18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome

19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome

19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)

20 Sickle Cell and Hemostasis Emergencies

20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed

21 Cardiopulmonary Emergencies

21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias

22 Neurologic and Infusion Emergencies

22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation

23 Family, Caregivers, and Social Integration

23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment

24 Development, Grief, Culture, and Community Resources

24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources

15.1 Pain Assessment and Management

Key Takeaways Explain This Topic AI

ONCC does not mandate a single pain scale: use NIPS or FLACC for infants and nonverbal children, Wong-Baker FACES for many preschoolers, and numeric 0–10 self-report when the child can rank; reassess after every intervention.

Name the type: nociceptive (surgery, mucositis, bone metastases), neuropathic (vincristine, dinutuximab, phantom limb), procedural, and sickle vaso-occlusion (signpost the SCD and emergency chapters; avoid meperidine).

A pediatric WHO ladder uses acetaminophen; NSAIDs only with platelet, renal, and high-dose-methotrexate caution; morphine, hydromorphone, or fentanyl for moderate-to-severe pain; around-the-clock plus breakthrough; PCA in older children without PCA-by-proxy.

Start constipation prophylaxis with the first opioid dose; keep naloxone for oversedation and respiratory depression, not as a first-line analgesic.

Sucrose, positioning, parental presence, distraction, and Child Life are interventions; gabapentin and methadone are adjuvants for neuropathic and complex pain as ordered.

Last updated: August 2026

CPHON Test Content Outline (TCO) IV.B.1 tests pain assessment and management as a general acute, chronic, and late effect. It is not the vaso-occlusive crisis (VOC) emergency playbook, not the dinutuximab infusion protocol, and not the gastrointestinal mucositis chapter restated. Those live elsewhere. Here the nurse names the pain type , matches a developmental tool , and runs a pediatric-adapted World Health Organization (WHO) analgesic ladder with nonpharmacologic partners. The Oncology Nursing Certification Corporation (ONCC) does not publish a single mandated pain scale. Do not invent one as exam fact. Match the tool to the child in front of you.

A 14-month-old after laparotomy who cannot self-report, a 5-year-old with mucositis pointing at a FACES card, a 9-year-old whose feet burn after vincristine , and a 16-year-old on patient-controlled analgesia (PCA) after amputation are the same domain at different ages.

Developmental tools: match the child, not a mythical ONCC scale

Pain is what the child—or a validated behavioral score—says it is, trended against that child's baseline . Infants and nonverbal children cannot give a 0–10 number. Use behavioral tools:

Neonatal Infant Pain Scale (NIPS) and related infant scales for neonates and young infants: facial expression, cry, breathing pattern, arms, legs, and arousal.

Face, Legs, Activity, Cry, Consolability (FLACC) for infants, toddlers, and nonverbal or developmentally delayed children. Each domain scores 0–2; the total is 0–10.

Wong-Baker FACES for many preschool and early school-age children who can point to a face that matches how they feel.

Numeric 0–10 self-report for older school-age children and adolescents who understand ranking.

Pediatric self-report is the gold standard whenever the child can do it. National Comprehensive Cancer Network ( NCCN ) adult oncology pain guidance and pediatric practice both emphasize regular screening, reassessment after every intervention , and a documented plan—not a branded instrument ONCC requires you to name.

Reassess after you intervene. A FLACC of 8 that falls to 2 after morphine and a parent in the crib is a plan that worked. A numeric 7 never rechecked after a breakthrough dose is incomplete. Do not withhold analgesia because the child is playing, sleeping between doses, or "should be used to ports." Do not demand a numeric score from a nonverbal 2-year-old because a unit poster shows a 0–10 line. A 4-year-old who says "my mouth is a 10" during methotrexate mucositis gets treatment for that 10, not a debate about whether FACES is too subjective.

Name the pain type

Nociceptive pain is tissue injury: surgical incision, bone metastases or marrow expansion, viscera after laparotomy, inflammatory mucositis . It often responds to acetaminophen, cautiously used nonsteroidal anti-inflammatory drugs (NSAIDs) , and opioids.

Neuropathic pain is nerve injury or nerve-targeted therapy. Vincristine produces stocking-glove burning, jaw pain, and dysesthesia (the neurologic-effects chapter owns foot drop and ileus; this chapter owns the burning). Dinutuximab (anti-GD2 for high-risk neuroblastoma) causes expected neuropathic pain that protocols treat with opioids plus a gabapentinoid ; the immunotherapy chapter owns capillary leak and stop parameters—this section owns the pain type. Phantom limb pain after amputation for osteosarcoma or Ewing sarcoma is neuropathic, not the child imagining the leg. Burning, shooting, allodynia, and "legs on fire" are neuropathic clues. Opioids help; gabapentin (or another gabapentinoid as ordered) and, in complex or opioid-refractory pain, methadone are the adjuvants to know. Do not withhold dinutuximab analgesia because pain "means it is working."

Procedural pain is needles, lumbar punctures, bone-marrow aspirations, and dressing changes. Treat the event, not only the diagnosis. Mucositis after high-dose methotrexate, anthracyclines, or radiation is inflammatory nociceptive pain that stops eating; oral care and scheduled opioids sit beside the gastrointestinal-effects chapter. Bone metastases and packed marrow produce deep, movement-related pain. VOC in sickle cell disease is ischemic nociceptive pain treated with age-appropriate opioids; avoid meperidine because the metabolite normeperidine lowers the seizure threshold. Full VOC titration, incentive spirometry, and acute-chest watch are signposted to the sickle-cell and later emergency chapters—do not restage the entire SCD pathway here.

WHO ladder, PCA, adjuvants, and opioid safety

A pediatric-adapted WHO analgesic ladder still organizes teaching:

Mild: acetaminophen on a scheduled or as-needed clock. In neutropenia, document doses so a home caregiver is not "treating fever" instead of coming in; acetaminophen for documented pain remains appropriate as ordered. NSAIDs (ibuprofen, ketorolac as ordered) help bone and inflammatory pain but carry platelet, gastritis, and renal caution. Hold NSAIDs when platelets are critically low, when the child is in a high-dose methotrexate window (clearance risk), or when creatinine is rising. Ketorolac is not automatically safe because it is not an opioid.

Moderate to severe: opioids— morphine , hydromorphone , fentanyl (including transdermal systems only in selected stable, opioid-tolerant severe pain). Dose by weight, titrate to comfort and respiratory status, and prefer the oral route when the gut works. Do not place a fentanyl patch on an opioid-naive 8-year-old for a one-time procedure. Avoid meperidine in SCD and as a routine pediatric oncology analgesic.

Around-the-clock (ATC) dosing for continuous pain (mucositis, bone mets, postoperative days) plus breakthrough doses for incident or end-of-dose pain. As-needed-only opioids for around-the-clock mucositis leave the child chasing pain all night.

PCA in older children and adolescents who understand the button: a continuous rate when indicated plus a lockout bolus. Parents and nurses do not push the button for a sleeping child ( no PCA-by-proxy ) unless a protocolized authorized-agent pathway exists. Teach the 16-year-old that the button treats pain, not boredom.

Adjuvants: gabapentin for neuropathic and dinutuximab pain; methadone for complex, escalating, or neuropathic-dominant pain under experienced prescribers (long half-life, QTc watch). Corticosteroids may reduce bone or inflammatory pain as ordered; they are not a secret opioid substitute.

Constipation prophylaxis starts the day the opioid starts: polyethylene glycol, senna as ordered, a stool record. Waiting three days without stool is the failure. Naloxone reverses oversedation and respiratory depression —it is not a first-line analgesic and not a bowel regimen. Dilute or low-dose naloxone infusions are sometimes used for opioid-induced pruritus or ileus as ordered. A child who will not arouse and whose respiratory rate is falling gets prompt naloxone and airway support, then a new pain plan so withdrawal and rebound pain are not the next injury.

Nonpharmacologic partners are interventions

Pharmacology without development is incomplete. Oral sucrose and nonnutritive sucking for infants during heel sticks and line access; positioning and swaddling; parental presence as the default, not a privilege; distraction (bubbles, tablets, music); and Child Life for procedural rehearsal, comfort holds, and medical play. A 3-year-old who watches a tablet during port access still needs a topical anesthetic and an honest warning, not a surprise stick. Cluster painful tasks when possible so the child is not poked hourly.

Pain picture Typical tool First-line cluster Trap

Infant / nonverbal postoperative NIPS or FLACC Acetaminophen ± opioid; sucrose; parent Demanding a 0–10 self-report

Preschool mucositis FACES plus behavior ATC opioid plus oral care; acetaminophen As-needed-only opioids

Vincristine or dinutuximab burning Self-report if able Opioid plus gabapentin as ordered Withholding because "it is working"

Adolescent bone mets / amputation Numeric 0–10; PCA if eligible ATC plus breakthrough; phantom-limb adjuvant PCA-by-proxy; skipped bowel regimen

SCD vaso-occlusion Age-appropriate scale Opioids; no meperidine NSAIDs alone for severe VOC; duplicating the emergency chapter

The CPHON product is a documented score that matches development, a named pain type, an opioid with a bowel plan, naloxone in the drawer for oversedation, and Child Life in the room for the needle—not a single ONCC-branded scale.

Loading diagram... Pediatric oncology pain: match the tool, name the type, run the ladder